RE:PartnershipIt's actually 6 years or more that they've beeen talking about partnerships. Not sure about the inept management or mediocre science though...either one can only take you so far. But quite frankly, I do have to wonder about management's sincerity in getting a deal done in a timey fashion, unless of course they are going door to door peddling snake oil concoctions that no Pharma will bother touching. I've given up on this second option a few years back because I have to believe that anyone in their right mind would have given up ages ago coming to a negotiating table only to regurgitate the same message year after year after year, unless they were truly carrying the goods.
So then, assuming Promis has the goods, not one interested Pharma party in over 6+ years of negotiations? Highly unlikely. Are Promis's demands preposterous? Perhaps.... but no middle ground whatsoever? I've heard of stalling tactics, but it's seems clearer now, more that ever with the approval of Eli Lilly's Donanemab's treatment drug that Promis is voluntarily taking a snails pace route in advancing its drug and /or striking a deal to let competitors cash in on their arguably inferior therapies allowing them to recuperate years of research costs before being eventually ousted by a potentially superior therapy. Sounds like a conspiracy? Perhaps, but it could be the only deal Promis struck with Pharmas. And maybe getting in line, sitting idly by, waiting for your turn for another 2-3 years didn't sit too well with Gail and that's why she high tailed it out of there only to be replaced by an interim CEO.
"Based on interactions with potential pharmaceutical partners, we believe our proprietary discovery platform and the resulting expanded portfolio offer real partnering opportunities. Antibody therapeutics targeting toxic forms of tau, TDP43 and, especially alpha-synuclein, are high on the list of partnering objectives for many companies in the field. We are actively pursuing partnering discussions for our developing portfolio as we continue to generate data in support of these programs", stated Dr. Goldstein.
https://stockhouse.com/news/press-releases/2018/11/20/promis-neurosciences-issues-year-to-date-update-highlighting-2018